Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11468896 | 0.79 | — | — | |
| SCHEMBL17060892 | 0.77 | CA2 (0.34) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL169923 | 0.76 | CA2 (0.46) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL60732 | 0.76 | CA2 (0.46) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL18065074 | 0.74 | ALDH1A1 (0.40) | TSHRUSP2CA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11604562 | 0.72 | CA2 (0.47) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL2943135 | 0.72 | CA1 (0.53) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL30296676 | 0.71 | TSHR (0.31) | TSHRUSP2CA1CA2ALDH1A1 | |
| Ethylene Glycol SCHEMBL5068932 | 0.71 | CA2 (0.42) | TSHRUSP2CA1CA2ALDH1A1 | |
| SCHEMBL5068919 | 0.68 | ALDH1A1 (0.43) | TSHRCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | MSR1, EDNRA, GPR174 | TSHR 850/4885USP2 4722/4885CA1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.